Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Arcus Biosciences, Inc.NYSE: RCUS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin declines year over year
Q2 FY2026 selling, general & admin of $24M fell 17.2% year over year, behind the -7.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 17.2% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.
Context
- Selling, general & admin amounted to 44.5% of revenue in FY2025, down 2.0 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $43.79M (-60.2%) for the fiscal year ending Dec 2026, a slowdown from the -8.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $24M-17.2% QoQ
- Last fiscal yearDec 2025
- $110M-8.3% YoY
- LTMJun 2026
- $106M-7.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 110M USD
- Year-over-year change
- -8.3%
- 4-year CAGR
- +11.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110M | -8.3% |
| FY2024 | 2024-12-31 | 120M | +2.6% |
| FY2023 | 2023-12-31 | 117M | +12.5% |
| FY2022 | 2022-12-31 | 104M | +44.4% |
| FY2021 | 2021-12-31 | 72M | — |
Selling, General & Admin vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 selling, general & admin of $106M is the 8th highest of the 9 companies compared; the peer median is $145.34M.
- Its year-over-year change of -7.8% is the lowest of 9, against a peer median of +21.6%.
- Selling, general & admin amounts to 90.6% of revenue for RCUS, versus a peer median of 213.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $192.66M | +74.7% | +69.3% | 42.7% | |
| LTM Mar 2026 | $187.06M | +11.8% | +14.0% | 283.2% | |
| LTM Sep 2026 | $185.41M | +24.0% | +12.7% | 101.6% | |
| LTM Jun 2026 | $151.65M | +125.3% | +39.4% | 213.2% | |
| LTM Jun 2026 | $139.03M | +19.2% | +2.4% | 3857.6% | |
| LTM Jun 2026 | $125.4M | +14.0% | +9.0% | 80.4% | |
| LTM Mar 2026 | $124.38M | +14.7% | +17.9% | 239.0% | |
| LTM Jun 2026 | $106M | -7.8% | +1.9% | 90.6% | |
| LTM Jun 2026 | $98.37M | +101.7% | +34.4% | — | |
| Peer median (excluding RCUS) | $145.34M | +21.6% | +16.0% | 213.2% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| Weighted Avg Shares | 69.35M | 72M | 74M | 90.1M | 107.4M |
| Weighted Avg Shares (Diluted) | 73.97M | 72M | 74M | 90.1M | 107.4M |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.